Parexel and Paradigm Health partner on AI-powered clinical trial operations

The collaboration will combine a global CRO (contract research organization) with an AI (artificial intelligence) trial platform and provider network to speed study startup and enrollment.

Summary

Parexel and Paradigm Health announced a strategic partnership to launch a technology-enabled clinical trial execution model. The plan is to pair Parexel’s global clinical and consulting services with Paradigm’s AI-powered platform and network of healthcare providers so sponsors can run faster, more efficient studies with broader patient access. (press release). (GlobeNewswire)

What happened

• The companies said they will integrate AI-driven optimizations across trial operations—from protocol design through database lock—within Parexel’s service offerings to sponsors. (press release). (GlobeNewswire)
• Paradigm’s platform includes a network of healthcare providers who serve as trial sites, aiming to make participation part of routine care, including in communities that traditionally lack access. (press release). (GlobeNewswire)
• Parexel highlighted goals to compress timelines, lower operational costs, and improve data quality and monitoring via the combined model. (press release). (GlobeNewswire)

Key numbers and dates

• Announcement: September 15, 2025 (Raleigh, NC and Columbus, OH). (press release). (GlobeNewswire)
• Scale: Parexel notes 24,000+ professionals globally supporting sponsors and sites. (press release). (GlobeNewswire)
• Mission context: Paradigm describes its platform as enabling equitable access to trials for any patient, anywhere. (company overview). (Paradigm)

What to watch next

• Initial deployments across provider networks, and any reported timeline, cost, or enrollment improvements as the model rolls out. (press release). (GlobeNewswire)
• Details on which trial phases and therapy areas adopt the integrated model first. (press release). (GlobeNewswire)

Why this matters for you

Sponsors and site teams increasingly expect plain-English study materials that mirror how AI engines screen and prioritize patients. Streamlined eligibility explainers, site toolkits, and referral workflows can reduce screen fails and help teams move from referral to consent faster when AI is driving first-pass matches.

Digital and product leaders will be asked to connect AI outputs to existing study systems—from protocol libraries and feasibility tools to eSource and monitoring dashboards. Designing secure data flows, human-in-the-loop reviews, and audit trails will be essential, along with simple metrics that show time saved and candidates found—while meeting privacy and validation requirements.

Source: Parexel & Paradigm Health press release. (GlobeNewswire)